CLL1-Targeting Antibody for Selective AML Cell Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute myeloid leukemia (AML) such as chemotherapy and allogeneic hematopoietic stem cell transplantation suffer from significant side effects and recurrence, with no effective anti-CLL1 antibodies available for targeted therapy.
Innovation Solution
Development of specific antibodies targeting CLL1, including specific CDR and LCDR sequences, which can be used in immunoconjugates and chimeric antigen receptors to enhance tumor targeting and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy drugs (daunorubicin, idarubicin, cytarabine) are used to treat AML, then tumor inhibition effect is improved, but side effects and recurrence increase
Solution Approach 1:
The patent extracts and isolates the specific target antigen CLL1 from the complex tumor environment, designing antibodies that specifically bind to CLL1 on AML cells. This extraction approach allows the treatment to target only the malignant cells expressing CLL1, leaving healthy cells unaffected, thereby achieving tumor inhibition without the broad toxic side effects of conventional chemotherapy.
Solution Approach 2:
The patent introduces antibodies as intermediary molecules that mediate between the immune system and AML cells. These antibodies specifically recognize and bind to CLL1 antigens on AML cells, serving as a bridge to activate immune-mediated destruction of tumor cells while avoiding direct toxic damage to healthy tissues that characterizes conventional chemotherapy.
2Reliability
If allogeneic hematopoietic stem cell transplantation is performed, then treatment effect is improved, but transplantation complications and recurrence increase
Solution Approach 1:
The patent extracts the essential therapeutic function of stem cell transplantation (targeted elimination of AML cells) while removing the complex and hazardous transplantation procedure. By using antibodies against CLL1, the treatment achieves similar therapeutic goals through a simpler, less invasive mechanism that avoids graft-versus-host disease and other transplantation-related complications.
3Reliability
If conventional chemotherapy is used, then initial tumor control is improved, but clinical compliance decreases due to side effects
Solution Approach 1:
The patent converts the previously harmful non-specific cytotoxicity of chemotherapy into beneficial specific targeting. By designing antibodies that specifically recognize CLL1 on AML cells, the treatment transforms the broad toxic effect into a selective anti-tumor action, thereby maintaining effective tumor control while dramatically reducing side effects to improve patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies demonstrate high specificity and binding ability to CLL1-positive cells, offering potential for effective treatment of AML and other myeloid leukemias with reduced side effects.
Implementation Method 1
The antibodies demonstrate high specificity and binding ability to CLL1-positive cells
Data Source
AI summary
Provided are a CLL1-targeting antibody and an application thereof. The CLL1-specific antibody has high affinity for CLL1, and after being prepared into a chimeric antigen receptor-modified T cells, has a significant killing effect on cells expressing CLL1.